GP515 是一种强效且具有选择性的腺苷激酶 (adenosine kinase) 抑制剂,其对人体的 IC50 值为 4 nM,具有组织保护作用,可在出血性休克后产生持久的肝脏微循环改善作用,可抑制 DSS 诱导的结肠炎中 IFNγ 的合成和 CD69 的表达,还表现出剂量依赖性的 TNF-α 生成抑制作用(IC50 值为 80 μM),且该抑制作用可被 cAMP 拮抗剂 (Rp)-cAMPS (MS-O46644) 逆转,可用于出血性休克和炎症性肠病的研究。
产品编号: MS-B88411 CAS No.: 144928-48-3 分子式: C10H13BrN6O3 分子量: 345.15
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

GP515 是一种强效且具有选择性的腺苷激酶 (adenosine kinase) 抑制剂,其对人体的 IC50 值为 4 nM,具有组织保护作用,可在出血性休克后产生持久的肝脏微循环改善作用,可抑制 DSS 诱导的结肠炎中 IFNγ 的合成和 CD69 的表达,还表现出剂量依赖性的 TNF-α 生成抑制作用(IC50 值为 80 μM),且该抑制作用可被 cAMP 拮抗剂 (Rp)-cAMPS (MS-O46644) 逆转,可用于出血性休克和炎症性肠病的研究。

生物实验数据

生物活性 GP515 is a potent and selective adenosine kinase inhibitor with an IC50 of 4 nM in humans that exerts tissue-protective effects, produces lasting improvements in hepatic microcirculation after hemorrhagic shock, inhibits IFNγ synthesis and CD69 expression in DSS-induced colitis, and exhibits dose-dependent inhibition of TNF-α production with an IC50 of 80 μM that is reversed by the cAMP antagonist (Rp)-cAMPS (MS-O46644), making it useful for research on hemorrhagic shock and inflammatory bowel disease.
体外研究
(In Vitro)

GP515 可强效且特异性地抑制分离得到的人心肌腺苷激酶,其 IC50 为 4 nM。
GP515 (2-20 μM;18 小时) 在常氧孵育 18 小时后,可使培养的大鼠心肌成肌细胞中 VEGF mRNA 的表达分别上调 1.67 倍和 1.82 倍。
GP515 (0.2-200 μM;18 小时) 在常氧孵育 18 小时后,可诱导培养的大鼠心肌成肌细胞中 VEGF 蛋白表达呈剂量依赖性升高,在最高浓度下升高幅度可达 54%。
GP515 (1 μM;12-24 小时) 在常氧孵育 12 小时后可显著上调培养大鼠心肌成肌细胞中的 VEGF 蛋白表达,且该效应可持续至 24 小时。
GP515 (2 μM;18 小时) 与腺苷脱氨酶共同孵育可完全阻断常氧孵育 18 小时后培养大鼠心肌成肌细胞中 VEGF 蛋白的诱导作用。
GP515 (20 μM;24 小时) 可将人脐静脉内皮细胞的增殖能力提升 98%,并在孵育 24 h 后使[3H]胸苷掺入量增加 82%,但对大鼠心肌成肌细胞的增殖无影响。
GP515 (20 μM;18 小时) 可在常氧条件下使培养的大鼠心肌成肌细胞中 VEGF 蛋白表达量提升 37%;在轻度缺氧 (10% O2) 孵育 18 h 后,该表达量可进一步提升 27%,但在重度缺氧 (1% O2) 条件下无作用。

ELISA Assay

Cell Line: cultured rat myocardial myoblasts (RMMs)
Concentration: 0.2 μM; 2 μM; 20 μM; 200 μM
Incubation Time: 18 h
Result: Increased VEGF protein levels to 1.99 ng/mg total cell protein (8% increase) at 0.2 μM.
Increased VEGF protein levels to 2.50 ng/mg total cell protein (36% increase) at 2 μM.
Increased VEGF protein levels to 2.56 ng/mg total cell protein (39% increase) at 20 μM.
Increased VEGF protein levels to 2.84 ng/mg total cell protein (54% increase) at 200 μM; control VEGF protein levels were 1.84 ng/mg total cell protein, with all increases statistically significant.

ELISA Assay

Cell Line: cultured rat myocardial myoblasts (RMMs)
Concentration: 1 μM
Incubation Time: 2 h; 6 h; 12 h; 24 h
Result: Did not significantly increase VEGF protein levels after 2 or 6 h of incubation.
Caused a significant 20% increase after 12 h.
Continued to increase levels such that by 24 h, levels were quantitatively similar to those induced by equimolar adenosine.

ELISA Assay

Cell Line: cultured rat myocardial myoblasts (RMMs)
Concentration: 2 μM (co-incubated with 10 U/mL adenosine deaminase)
Incubation Time: 18 h
Result: Co-incubation with adenosine deaminase completely blocked the GP515-induced increase in VEGF protein, reducing levels to 0.75 ng/mg total cell protein, a 60% decrease compared to control levels of 1.84 ng/mg total cell protein.

Cell Proliferation Assay

Cell Line: human umbilical vein endothelial cells (HUVECs), rat myocardial myoblasts (RMMs)
Concentration: 20 μM
Incubation Time: 24 h
Result: Increased HUVEC cell number by 98% (from control 8.5 × 105 cells/well).
Increased [3H]thymidine incorporation by 82% (from control 11.91 × 103 cpm/well), with both changes statistically significant.
Had no effect on RMM proliferation.

ELISA Assay

Cell Line: cultured rat myocardial myoblasts (RMMs)
Concentration: 20 μM
Incubation Time: 18 h (under normoxia, mild hypoxia, severe hypoxia)
Result: Increased VEGF protein levels by 37% (to 2.79 ng/mg total cell protein) compared to normoxic control levels of 2.04 ng/mg total cell protein under normoxia.
Increased VEGF protein levels by an additional 27% (to 4.17 ng/mg total cell protein) compared to mild hypoxia control levels of 3.29 ng/mg total cell protein under mild hypoxia.
Had no effect on VEGF protein levels (5.84 ng/mg total cell protein vs.
severe hypoxia control levels of 6.06 ng/mg total cell protein) under severe hypoxia.
体内研究
(In Vivo)

GP515 (0.25 mg/kg;静脉注射;持续输注 1 小时;失血性低血压发作 90 分钟后开始给药) 在雌性 Sprague-Dawley 大鼠 (200-250 g) 失血性休克后全身给药,可显著改善休克后 2 天的肝脏微循环参数 (肝窦血流量、直径和灌注指数),且这些参数在第 5 天恢复正常。

Animal Model: Sprague-Dawley (female, 200-250 g, pressure-controlled hemorrhagic hypotension induced by blood withdrawal to maintain mean arterial pressure at 40 mmHg for 90 minutes, followed by resuscitation with 60% shed blood and lactate Ringer’s solution)
Dosage: 0.25 mg/kg
Administration: i.v.; continuous infusion over 1 hour; starting 90 minutes after onset of hemorrhagic hypotension
Result: Increased sinusoidal blood flow to 40833 µm3/s, mean sinusoidal diameter to 12.08 µm, and perfusion index to 91.5% at 2 days post-shock, with all values significantly higher than placebo.
Normalized sinusoidal diameters, blood flow, and perfusion index by 5 days post-shock, with no significant difference from placebo-treated rats.

化学信息

分子量 345.15
分子式 C10H13BrN6O3
CAS No. 144928-48-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础